$10.69
-0.13-1.20%
At close: May 8, 5:00 PM EST
Santen Pharmaceutical (SNPHY) last issued guidance on February 6, 2025 for fiscal year 2024. The company guided earnings per share in the range of $0.77 - $0.77, compared to a consensus EPS estimate of . Santen Pharmaceutical also guided revenue in the range of $1.98B - $1.98B for the period.
Compared to prior guidance, Santen Pharmaceutical raised its revenue forecast from a prior range of $1.93B - $1.93B.
Santen Pharmaceutical has issued 4 guidance updates between August 4, 2022 and February 6, 2025. During this period, the company raised its outlook 1 time and lowered it 1 time, providing investors with insight into management's evolving expectations.
Latest Guidance Date
Feb 6, 2025
Guidance Period
Full Year 2024
EPS Guidance Range
$0.77 - $0.77
Revenue Guidance Range
$1.98B - $1.98B
Santen Pharmaceutical Guidance History
Review all historical guidance issued by Santen Pharmaceutical, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Santen Pharmaceutical (SNPHY)?
The most recent guidance for Santen Pharmaceutical (SNPHY) was reported on February 6, 2025 for the fiscal year 2024. Santen Pharmaceutical forecasted revenue between $1.98B and $1.98B for the period.
What revenue range did Santen Pharmaceutical (SNPHY) guide for?
Santen Pharmaceutical (SNPHY) guided revenue in the range of $1.98B to $1.98B for the fiscal year 2024.
Did Santen Pharmaceutical (SNPHY) raise or lower guidance?
Santen Pharmaceutical (SNPHY) raised its revenue guidance from a prior range of $1.93B - $1.93B to $1.98B - $1.98B for the fiscal year 2024.
When did Santen Pharmaceutical (SNPHY) last issue guidance?
Santen Pharmaceutical (SNPHY) last issued guidance on February 6, 2025 for the fiscal year 2024.
